Trial
NCT06231641
The Effects of Lemborexant on the Ability to Sleep During Daytime
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Collaborators
—
Condition
Shift-Work Sleep Disorder
Intervention
Lemborexant 5 MG [Dayvigo]
Why stopped
In agreement with all parties, the project was closed on March 31 due to recruitment challenges.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-28